FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2341828462> ?p ?o ?g. }

• W2341828462 abstract "Abstract Introduction Patients with relapsed or refractory aggressive non Hodgkin B-cell lymphomas (NHL) not eligible to high dose chemotherapy and transplantation had a dismal prognosis. Lenalidomide showed activity in this setting as single agent or in combination. On this basis, we conducted a single center retrospective study to investigate efficacy and safety of lenalidomide alone or in association with rituximab or steroids in patients with heavily pretreated aggressive B-cell NHL. Methods Primary end points of the study were response rate (RR), defined as complete response (CR), partial response (PR) and stable disease (SD), and duration of response (DOR); secondary end points were feasibility and safety. Inclusion criteria for the analysis were: patients with relapsed/refractory aggressive B-cell NHL, aged >18 years, treated with lenalidomide between August 2007 to June 2012. Treatment scheme were: standard dose of oral lenalidomide 25 mg/day for 21 days every 28 days as single agent; standard dose of lenalidomide with the same schedule in association to weekly dexamethasone (20 mg bolus); lenalidomide 20 mg/day for 21 days every 28 days in combination with rituximab (375 mg/sqm) every 28 days. Patients were treated until disease progression or unacceptable toxicities. Results A total of 53 patients were analyzed. Different histotypes of NHL were included in the study: 34 diffuse large B-cell lymphomas (DLBCL), 11 mantle cell, 5 follicular, 2 primitive mediastinal B-cell and one Burkitt lymphoma. At relapsed before lenalidomide treatment, the majority of the patients presented an advanced disease: 40 (75%) stage 3-4; intermediate high/high risk international prognostic index (IPI) 23 (43%). Bone marrow was involved in 20 (38%) patients and 20 (38%) cases presented a bulky disease. Prior treatment lines were as follows: 8 (15%) patients received lenalidomide at first relapse while 24 (45%) underwent more than 3 previous lines of therapy; 14 (26%) patients received high dose chemotherapy and autologous stems cell transplant, one (2%) patient was allogenic transplanted and 4 (8%) did both before lenalidomide. All patients analyzed received lenalidomide: 31 patients (58%) underwent lenalidomide as single agent, 11 (21%) received a combination scheme of lenalidomide plus rituximab and 11 cases (21%) were treated with lenalidomide plus steroids. Median time from diagnosis and the beginning of lenalidomide was 25,3 months (3,7- 145,9), while median time from last previous therapy and lenalidomide treatment was 3,2 months (0,4- 38). At the time of this analysis response assessment was done in 51 patients: Response rate was 35% (18 patients), with CR 8 (15%), PR 5 (10%), SD 5 (10%). All patients who obtained CR underwent more than 3 courses of therapy, while among 31 patients who did not respond to treatment, 21 failures occurred during the first three cycles. Concerning different schemes of therapy: in the arm treated with lenalidomide as single agent RR was 24%, among patients underwent lenalidomide plus rituximab was 55% and in the group receiving lenalidomide plus steroid 45%. Among 34 DLBCL patients, RR was 41% (n= 14: CR 5, PR 4, SD 5), while in 11 patients affected by mantle cell lymphoma RR was 27% (n= 3: CR2, PR 1). Median DOR for all 18 responding patients was 12 months (0,2-24). At a median follow-up of 20 months, 5 patients were in stable CR, 7 continued lenalidomide, 11 relapsed and 28 died. Patients received a total of 257 cycles of lenalidomide, of which 25 were earlier interrupted and 48 were reduced in dose or duration; 50% of patients had at least one interruption in the planned treatment, however globally 91% of the expected dose was given. One patient died due to heart failure during the treatment. Toxicity was globally mild: most common grade 3-4 adverse events were neutropenia (19%), anemia (17%) and thrombocytopenia (17%). Five patients had grade 3-4 infections and 3 patients had thromboembolic events (only one grade 3). Two cases of neuropathies, both grade ≤ 2 were observed. Conclusions Lenalidomide single agent or in association with rituximab or steroids is effective and safe in patients with relapsed or refractory aggressive B-cell NHL, showing a promising response rate also in patients with heavily pretreated disease and with a mild toxicity profile. Disclosures: Vitolo: Roche: Speakers Bureau; Celgene: Speakers Bureau; Takeda: Speakers Bureau." @default.
• W2341828462 created "2016-06-24" @default.
• W2341828462 creator A5000403848 @default.
• W2341828462 creator A5002911147 @default.
• W2341828462 creator A5014255803 @default.
• W2341828462 creator A5016042168 @default.
• W2341828462 creator A5020978640 @default.
• W2341828462 creator A5024504422 @default.
• W2341828462 creator A5026430732 @default.
• W2341828462 creator A5036765926 @default.
• W2341828462 creator A5045965829 @default.
• W2341828462 creator A5054623894 @default.
• W2341828462 creator A5063805789 @default.
• W2341828462 creator A5070003191 @default.
• W2341828462 creator A5074069337 @default.
• W2341828462 creator A5076353357 @default.
• W2341828462 creator A5087294312 @default.
• W2341828462 creator A5088168371 @default.
• W2341828462 date "2013-11-15" @default.
• W2341828462 modified "2023-09-28" @default.
• W2341828462 title "Relapsed Or Refractory Aggressive Non Hodgkin B-Cell Lymphomas Treated With Lenalidomide With/Without Rituximab Or Steroids: A Single Center Restrospective Study" @default.
• W2341828462 doi "https://doi.org/10.1182/blood.v122.21.5119.5119" @default.
• W2341828462 hasPublicationYear "2013" @default.
• W2341828462 type Work @default.
• W2341828462 sameAs 2341828462 @default.
• W2341828462 citedByCount "0" @default.
• W2341828462 crossrefType "journal-article" @default.
• W2341828462 hasAuthorship W2341828462A5000403848 @default.
• W2341828462 hasAuthorship W2341828462A5002911147 @default.
• W2341828462 hasAuthorship W2341828462A5014255803 @default.
• W2341828462 hasAuthorship W2341828462A5016042168 @default.
• W2341828462 hasAuthorship W2341828462A5020978640 @default.
• W2341828462 hasAuthorship W2341828462A5024504422 @default.
• W2341828462 hasAuthorship W2341828462A5026430732 @default.
• W2341828462 hasAuthorship W2341828462A5036765926 @default.
• W2341828462 hasAuthorship W2341828462A5045965829 @default.
• W2341828462 hasAuthorship W2341828462A5054623894 @default.
• W2341828462 hasAuthorship W2341828462A5063805789 @default.
• W2341828462 hasAuthorship W2341828462A5070003191 @default.
• W2341828462 hasAuthorship W2341828462A5074069337 @default.
• W2341828462 hasAuthorship W2341828462A5076353357 @default.
• W2341828462 hasAuthorship W2341828462A5087294312 @default.
• W2341828462 hasAuthorship W2341828462A5088168371 @default.
• W2341828462 hasConcept C126322002 @default.
• W2341828462 hasConcept C141071460 @default.
• W2341828462 hasConcept C143998085 @default.
• W2341828462 hasConcept C2776063141 @default.
• W2341828462 hasConcept C2777058707 @default.
• W2341828462 hasConcept C2777525834 @default.
• W2341828462 hasConcept C2779338263 @default.
• W2341828462 hasConcept C2780401358 @default.
• W2341828462 hasConcept C2780653079 @default.
• W2341828462 hasConcept C71924100 @default.
• W2341828462 hasConcept C90924648 @default.
• W2341828462 hasConceptScore W2341828462C126322002 @default.
• W2341828462 hasConceptScore W2341828462C141071460 @default.
• W2341828462 hasConceptScore W2341828462C143998085 @default.
• W2341828462 hasConceptScore W2341828462C2776063141 @default.
• W2341828462 hasConceptScore W2341828462C2777058707 @default.
• W2341828462 hasConceptScore W2341828462C2777525834 @default.
• W2341828462 hasConceptScore W2341828462C2779338263 @default.
• W2341828462 hasConceptScore W2341828462C2780401358 @default.
• W2341828462 hasConceptScore W2341828462C2780653079 @default.
• W2341828462 hasConceptScore W2341828462C71924100 @default.
• W2341828462 hasConceptScore W2341828462C90924648 @default.
• W2341828462 hasLocation W23418284621 @default.
• W2341828462 hasOpenAccess W2341828462 @default.
• W2341828462 hasPrimaryLocation W23418284621 @default.
• W2341828462 hasRelatedWork W2020428172 @default.
• W2341828462 hasRelatedWork W2098002594 @default.
• W2341828462 hasRelatedWork W2169014774 @default.
• W2341828462 hasRelatedWork W2253747904 @default.
• W2341828462 hasRelatedWork W2345799557 @default.
• W2341828462 hasRelatedWork W2386817084 @default.
• W2341828462 hasRelatedWork W2537548903 @default.
• W2341828462 hasRelatedWork W2549408207 @default.
• W2341828462 hasRelatedWork W2550172655 @default.
• W2341828462 hasRelatedWork W2577306999 @default.
• W2341828462 hasRelatedWork W2583904068 @default.
• W2341828462 hasRelatedWork W2586435830 @default.
• W2341828462 hasRelatedWork W2590111115 @default.
• W2341828462 hasRelatedWork W2962056638 @default.
• W2341828462 hasRelatedWork W2980239838 @default.
• W2341828462 hasRelatedWork W2992932944 @default.
• W2341828462 hasRelatedWork W2993051492 @default.
• W2341828462 hasRelatedWork W2994047002 @default.
• W2341828462 hasRelatedWork W3030292181 @default.
• W2341828462 hasRelatedWork W386940765 @default.
• W2341828462 isParatext "false" @default.
• W2341828462 isRetracted "false" @default.
• W2341828462 magId "2341828462" @default.
• W2341828462 workType "article" @default.